Cesca Therapeutics appoints Dr Xiaochun Xu to the Board of Directors

– USA, CA – Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Dr Xiaochun Xu (44) has been appointed to the Company’s Board of Directors.

Dr. Xu is the Founder, Chairman and CEO of Boyalife Group. He received his Ph.D. degree in Immunology from Washington University School of Medicine (St. Louis, USA) and an Executive MBA degree from Emory University (Atlanta, USA). Dr. Xu has over 15 years of managerial experience in biomedicine and the pharmaceutical industry and has been involved in the discovery and development of several blockbuster drugs. Since 2000 he served as a Project Leader at Pfizer, as a Director of Research at two publicly-traded companies and as a Vice President at Founder Group, a major Chinese technology conglomerate with interests in information technology, pharmaceuticals, real estate, finance, and commodities trading. Founder Group was established by Peking University in 1986. It currently has six public companies listed on the stock exchanges of Shanghai, Shenzhen and Hong Kong, and more than 80 independently funded enterprises and joint ventures.

Dr. Xu’s expertise spans several diverse therapeutic arenas including arthritis and inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. He has authored over 40 publications and won several international awards from various professional societies for excellence in biomedical research.

Craig Moore, Cesca’s Chairman, commented, “We are very pleased to have Dr. Xu join our Board of Directors. His experience in international markets, coupled with his involvement in research and commercialization of stem cell products, will be highly valued by both the Company and the Company’s Board. We look forward to the contributions he will make as we work together to build a world class organization and grow the Company”.

Dr Xiaochun Xu added, “Boyalife’s investment in Cesca is a strategic investment and a representation of the great value and synergy we see in working together. The Company’s ongoing phase III clinical program for the treatment of patients with late stage critical limb ischemia represents a best-in-class approach in its category. If approved, it will address a severe medical condition and a substantial unmet medical need. It will benefit tens of thousands of patients with limb ischemia and related conditions. As a new member of the Board of Directors, I look forward with enthusiasm to working with the management team to strengthen the therapeutic program and help ensure healthy growth of the Company.”

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (NASDAQ:KOOL), is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. We are a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>